Anne Douar, Chief Development Officer of Vivet Therapeutics, will give a presentation (“Manufacturing of a New Gene Therapy Product: Long Term Impact from Early Decision to Selection for Phase I to BLA / Commercial Strategy”) during the 3rd Annual Gene Therapy for Rare Disorders Europe conference in London on Oct. 16th at 11.15am